| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-7 Days |
| Number of Subjects | 220 |
| Sex | Both Genders |
| Age Range | 1-6, 7-12, 13-17 |
| Body Types | Average |
Supplementation of the standard doses of EPs7630 to children under six years of age (10 drops thrice daily), above 12 (30 drops thrice daily) or between the two ages (20 drops thrice daily) for one week around meals noted significant reductions in overall symptoms with the onset of symptom reduction occurring within 3-4 days.
